<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24794538</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>01</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2212-4934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>55</Volume>
            <PubDate>
              <Year>2014</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advances in biological regulation</Title>
          <ISOAbbreviation>Adv Biol Regul</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Signaling specificity in the Akt pathway in biology and disease.</ArticleTitle>
        <Pagination>
          <StartPage>28</StartPage>
          <EndPage>38</EndPage>
          <MedlinePgn>28-38</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbior.2014.04.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2212-4926(14)00003-7</ELocationID>
        <Abstract>
          <AbstractText>Akt/PKB is a key master regulator of a wide range of physiological functions including metabolism, proliferation, survival, growth, angiogenesis and migration and invasion. The Akt protein kinase family comprises three highly related isoforms encoded by different genes. The initial observation that the Akt isoforms share upstream activators as well as several downstream effectors, together with the high sequence homology suggested that their functions were mostly redundant. By contrast, an increasing body of evidence has recently uncovered the concept of Akt isoform signaling specificity, supported by distinct phenotypes displayed by animal strains genetically modified for each of the three genes, as well as by the identification of isoform-specific substrates and association with discrete subcellular locations. Given that Akt is regarded as a promising therapeutic target in a number of pathologies, it is essential to dissect the relative contributions of each isoform, as well as the degree of compensation in pathophysiological function. Here we summarize our view of how Akt selectivity is achieved in the context of subcellular localization, isoform-specific substrate phosphorylation and context-dependent functions in normal and pathophysiological settings.</AbstractText>
          <CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Toker</LastName>
            <ForeName>Alex</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: atoker@bidmc.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marmiroli</LastName>
            <ForeName>Sandra</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Medicine, Dentistry and Morphology, University of Modena and Reggio Emilia, Italy. Electronic address: sandra.marmiroli@unimore.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA122099</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA177910</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>04</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Adv Biol Regul</MedlineTA>
        <NlmUniqueID>101572336</NlmUniqueID>
        <ISSNLinking>2212-4926</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034904">Lamin Type A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076225">Mechanistic Target of Rapamycin Complex 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.16</RegistryNumber>
          <NameOfSubstance UI="C400601">PHLPP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.16</RegistryNumber>
          <NameOfSubstance UI="D010749">Phosphoprotein Phosphatases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.16</RegistryNumber>
          <NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034904" MajorTopicYN="N">Lamin Type A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076225" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010749" MajorTopicYN="N">Phosphoprotein Phosphatases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Akt</Keyword>
        <Keyword MajorTopicYN="N">Cancer</Keyword>
        <Keyword MajorTopicYN="N">Nucleus</Keyword>
        <Keyword MajorTopicYN="N">PI 3-Kinase</Keyword>
        <Keyword MajorTopicYN="N">Protein kinase</Keyword>
        <Keyword MajorTopicYN="N">Signaling</Keyword>
      </KeywordList>
      <CoiStatement><b>Conflict of Interest</b>. None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24794538</ArticleId>
        <ArticleId IdType="mid">NIHMS588430</ArticleId>
        <ArticleId IdType="pmc">PMC4062840</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jbior.2014.04.001</ArticleId>
        <ArticleId IdType="pii">S2212-4926(14)00003-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9094314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal. 2009;2:pe27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19383978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, et al.  Role of translocation in the activation and function of protein kinase B. The Journal of biological chemistry. 1997;272:31515–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9395488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer research. 2003;63:196–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12517798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bae SS, Cho H, Mu J, Birnbaum MJ. Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. The Journal of biological chemistry. 2003;278:49530–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14522993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Advances in enzyme regulation. 2011;51:37–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21035501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bavelloni A, Santi S, Sirri A, Riccio M, Faenza I, Zini N, et al.  Phosphatidylinositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells. Journal of cell science. 1999;112 (Pt 5):631–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9973598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertacchini J, Beretti F, Cenni V, Guida M, Gibellini F, Mediani L, et al.  The protein kinase Akt/PKB regulates both prelamin A degradation and Lmna gene expression. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2013;27:2145–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23430973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBa/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival. Molecular cell. 2008 In Press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18439899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Molecular cell. 2007;25:917–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17386267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calleja V, Laguerre M, Larijani B. Role of the C-terminal regulatory domain in the allosteric inhibition of PKB/Akt. Advances in biological regulation. 2012;52:46–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21930144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448:439–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17611497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenni V, Bavelloni A, Beretti F, Tagliavini F, Manzoli L, Lattanzi G, et al.  Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic differentiation upon cellular exposure to H(2)O(2) Molecular biology of the cell. 2011;22:2946–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3154889</ArticleId>
            <ArticleId IdType="pubmed">21737686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenni V, Bertacchini J, Beretti F, Lattanzi G, Bavelloni A, Riccio M, et al.  Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells. J Proteome Res. 2008;7:4727–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18808171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenni V, Sirri A, Riccio M, Lattanzi G, Santi S, de Pol A, et al.  Targeting of the Akt/PKB kinase to the actin skeleton. Cell Mol Life Sci. 2003;60:2710–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14685694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan TO, Tsichlis PN. PDK2: a complex tail in one Akt. Science’s STKE: signal transduction knowledge environment. 2001;2001:pe1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11752635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen CH, Kiyan V, Zhylkibayev AA, Kazyken D, Bulgakova O, Page KE, et al.  Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism. The Journal of biological chemistry. 2013;288:27019–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3779703</ArticleId>
            <ArticleId IdType="pubmed">23928304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen CH, Shaikenov T, Peterson TR, Aimbetov R, Bissenbaev AK, Lee SW, et al.  ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor. Sci Signal. 2011;4:ra10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21343617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, et al.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes &amp; development. 2001;15:2203–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC312770</ArticleId>
            <ArticleId IdType="pubmed">11544177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cellular signalling. 2009;21:470–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2719559</ArticleId>
            <ArticleId IdType="pubmed">19110052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin YR, Toker A. The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration. Molecular cell. 2010;38:333–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2872630</ArticleId>
            <ArticleId IdType="pubmed">20471940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Cancer research. 2014;74:964–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3946502</ArticleId>
            <ArticleId IdType="pubmed">24335962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd, et al.  Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Science. 2001a;292:1728–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11387480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. The Journal of biological chemistry. 2001b;276:38349–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11533044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dechat T, Adam SA, Goldman RD. Nuclear lamins and chromatin: when structure meets function. Advances in enzyme regulation. 2009;49:157–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3253622</ArticleId>
            <ArticleId IdType="pubmed">19154754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer research. 2009;69:5057–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4151524</ArticleId>
            <ArticleId IdType="pubmed">19491266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dummler B, Tschopp O, Hynx D, Yang ZZ, Dirnhofer S, Hemmings BA. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Molecular and cellular biology. 2006;26:8042–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1636753</ArticleId>
            <ArticleId IdType="pubmed">16923958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eriksson JE, Dechat T, Grin B, Helfand B, Mendez M, Pallari HM, et al.  Introducing intermediate filaments: from discovery to disease. The Journal of clinical investigation. 2009;119:1763–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2701876</ArticleId>
            <ArticleId IdType="pubmed">19587451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. The Journal of biological chemistry. 2004;279:41189–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15262962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Follo MY, Faenza I, Piazzi M, Blalock WL, Manzoli L, McCubrey JA, et al.  Nuclear PI-PLCbeta1: an appraisal on targets and pathology. Advances in biological regulation. 2014;54:2–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24296032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Follo MY, Marmiroli S, Faenza I, Fiume R, Ramazzotti G, Martelli AM, et al.  Nuclear phospholipase C beta1 signaling, epigenetics and treatments in MDS. Advances in biological regulation. 2013;53:2–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23058275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Molecular cell. 2005;18:13–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15808505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, et al.  Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. The Journal of clinical investigation. 2003;112:197–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC164287</ArticleId>
            <ArticleId IdType="pubmed">12843127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochimica et biophysica acta. 2004;1697:3–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15023346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harbor perspectives in biology. 2012;4:a011189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3428770</ArticleId>
            <ArticleId IdType="pubmed">22952397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, Hemmings BA, et al.  Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Molecular and cellular biology. 2006;26:8267–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1636765</ArticleId>
            <ArticleId IdType="pubmed">16982699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer research. 2004;64:3171–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15126356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, et al.  MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal. 2009;2:ra62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2862216</ArticleId>
            <ArticleId IdType="pubmed">19825827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. The Journal of cell biology. 2005;171:1023–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2171329</ArticleId>
            <ArticleId IdType="pubmed">16365168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, et al.  Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Molecular and cellular biology. 2002;22:7831–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC134727</ArticleId>
            <ArticleId IdType="pubmed">12391152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keune W, Bultsma Y, Sommer L, Jones D, Divecha N. Phosphoinositide signalling in the nucleus. Advances in enzyme regulation. 2011;51:91–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21035491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunkel MT, Ni Q, Tsien RY, Zhang J, Newton AC. Spatio-temporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. The Journal of biological chemistry. 2005;280:5581–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2913970</ArticleId>
            <ArticleId IdType="pubmed">15583002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunz J, Henriquez R, Schneider U, Deuter RM, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993;73:585–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8387896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambrecht C, Haesen D, Sents W, Ivanova E, Janssens V. Structure, regulation, and pharmacological modulation of PP2A phosphatases. Methods Mol Biol. 2013;1053:283–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23860660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leslie NR, Maccario H, Spinelli L, Davidson L. The significance of PTEN’s protein phosphatase activity. Advances in enzyme regulation. 2009;49:190–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19168090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA, et al.  Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:4134–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1390746</ArticleId>
            <ArticleId IdType="pubmed">16537497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, et al.  Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther. 2008;7:2621–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2727864</ArticleId>
            <ArticleId IdType="pubmed">18790745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mall M, Walter T, Gorjanacz M, Davidson IF, Nga Ly-Hartig TB, Ellenberg J, et al.  Mitotic lamin disassembly is triggered by lipid-mediated signaling. The Journal of cell biology. 2012;198:981–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3444782</ArticleId>
            <ArticleId IdType="pubmed">22986494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Cantley LC. Hitting the target: emerging technologies in the search for kinase substrates. Science’s STKE: signal transduction knowledge environment. 2002;2002:PE49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12475999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756685</ArticleId>
            <ArticleId IdType="pubmed">17604717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maraldi NM, Lattanzi G, Cenni V, Bavelloni A, Marmiroli S, Manzoli FA. Laminopathies and A-type lamin-associated signalling pathways. Advances in enzyme regulation. 2010;50:248–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19917303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marmiroli S, Bertacchini J, Beretti F, Cenni V, Guida M, De Pol A, et al.  A-type lamins and signaling: the PI 3-kinase/Akt pathway moves forward. Journal of cellular physiology. 2009;220:553–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19479937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer research. 2007;67:167–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17210696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, et al.  The emerging multiple roles of nuclear Akt. Biochimica et biophysica acta. 2012;1823:2168–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22960641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moritz A, Li Y, Guo A, Villen J, Wang Y, MacNeill J, et al.  Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Science signaling. 2010;3:ra64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137639</ArticleId>
            <ArticleId IdType="pubmed">20736484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris GE. The role of the nuclear envelope in Emery-Dreifuss muscular dystrophy. Trends in molecular medicine. 2001;7:572–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11733221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neri LM, Bortul R, Tabellini G, Borgatti P, Baldini G, Celeghini C, et al.  Erythropoietin-induced erythroid differentiation of K562 cells is accompanied by the nuclear translocation of phosphatidylinositol 3-kinase and intranuclear generation of phosphatidylinositol (3,4,5) trisphosphate. Cellular signalling. 2002;14:21–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11747985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annual review of pharmacology and toxicology. 2014;54:537–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4082184</ArticleId>
            <ArticleId IdType="pubmed">24392697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, et al.  Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:19368–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3511101</ArticleId>
            <ArticleId IdType="pubmed">23134728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S, et al.  Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:3028–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC16186</ArticleId>
            <ArticleId IdType="pubmed">10716693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson RT, Schreiber SL. Kinase phosphorylation: Keeping it all in the family. Curr Biol. 1999;9:R521–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10421571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiao M, Iglehart JD, Pardee AB. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer research. 2007;67:5293–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17545609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosner M, Hengstschlager M. Detection of cytoplasmic and nuclear functions of mTOR by fractionation. Methods Mol Biol. 2012;821:105–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22125063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16915295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7518356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saji M, Vasko V, Kada F, Allbritton EH, Burman KD, Ringel MD. Akt1 contains a functional leucine-rich nuclear export sequence. Biochemical and biophysical research communications. 2005;332:167–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15896313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, et al.  Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Molecular cell. 2014;53:577–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3947584</ArticleId>
            <ArticleId IdType="pubmed">24462114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheid MP, Parsons M, Woodgett JR. Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Molecular and cellular biology. 2005;25:2347–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1061613</ArticleId>
            <ArticleId IdType="pubmed">15743829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S, et al.  Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circulation research. 2004;94:884–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14988230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toker A. Achieving specificity in Akt signaling in cancer. Advances in biological regulation. 2012;52:78–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3614006</ArticleId>
            <ArticleId IdType="pubmed">21986444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, et al.  Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005;132:2943–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15930105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandromme M, Rochat A, Meier R, Carnac G, Besser D, Hemmings BA, et al.  Protein kinase B beta/Akt2 plays a specific role in muscle differentiation. The Journal of biological chemistry. 2001;276:8173–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11087731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Basson MD. Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion. Experimental cell research. 2008;314:286–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2180395</ArticleId>
            <ArticleId IdType="pubmed">17825284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warfel NA, Niederst M, Stevens MW, Brennan PM, Frame MC, Newton AC. Mislocalization of the E3 ligase, beta-transducin repeat-containing protein 1 (beta-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. The Journal of biological chemistry. 2011;286:19777–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103356</ArticleId>
            <ArticleId IdType="pubmed">21454620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xuan Nguyen TL, Choi JW, Lee SB, Ye K, Woo SD, Lee KH, et al.  Akt phosphorylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cells. Biochemical and biophysical research communications. 2006;349:789–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16956580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Molecular cell. 2005;20:539–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16307918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3398461</ArticleId>
            <ArticleId IdType="pubmed">18794884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou GL, Tucker DF, Bae SS, Bhatheja K, Birnbaum MJ, Field J. Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. The Journal of biological chemistry. 2006;281:36443–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17012749</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
